Comparison of Prosigna® Assay and Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Results in Early-Stage Breast Cancer Patients.

ABSTRACT:

Background

The decision-making process regarding adjuvant treatment in estrogen receptor-positive (ER+), HER2-negative early-stage breast cancer (EBC) is often not sufficient, when based on established clinicopathological parameters. Additional prognostic tests could facilitate these decisions. This paper compares the well-validated invasion marker urokinase plasminogen activator/plasminogen activator inhibitor-1 (uPA/PAI-1) with the Prosigna® assay, which is based on the PAM50 gene signature. Prosigna® also provides a prognostic risk assessment (risk of recurrence, Prosigna®-ROR), taking tumor burden and the intrinsic molecular subtype into account.

Methods

From October 2013 to April 2014, we selected 42 postmenopausal EBC patients (ER+/HER2-) from the database of the Breas

SUBMITTER: Rickerl L 

PROVIDER: S-EPMC12826793 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature